| Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer RL Milne, KB Kuchenbaecker, K Michailidou, J Beesley, S Kar, ... Nature genetics 49 (12), 1767-1778, 2017 | 353 | 2017 |
| EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme BW Day, BW Stringer, F Al-Ejeh, MJ Ting, J Wilson, KS Ensbey, ... Cancer cell 23 (2), 238-248, 2013 | 254 | 2013 |
| A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer L Wu, W Shi, J Long, X Guo, K Michailidou, J Beesley, MK Bolla, XO Shu, ... Nature genetics 50 (7), 968-978, 2018 | 213 | 2018 |
| Harnessing the complexity of DNA-damage response pathways to improve cancer treatment outcomes F Al-Ejeh, R Kumar, A Wiegmans, SR Lakhani, MP Brown, KK Khanna Oncogene 29 (46), 6085-6098, 2010 | 173 | 2010 |
| Breast cancer stem cells: treatment resistance and therapeutic opportunities F Al-Ejeh, CE Smart, BJ Morrison, G Chenevix-Trench, JA López, ... Carcinogenesis 32 (5), 650-658, 2011 | 162 | 2011 |
| G9a drives hypoxia-mediated gene repression for breast cancer cell survival and tumorigenesis F Casciello, F Al-Ejeh, G Kelly, DJ Brennan, SF Ngiow, A Young, T Stoll, ... Proceedings of the National Academy of Sciences 114 (27), 7077-7082, 2017 | 124 | 2017 |
| Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer MA Ferreira, ER Gamazon, F Al-Ejeh, K Aittomäki, IL Andrulis, ... Nature communications 10 (1), 1741, 2019 | 121 | 2019 |
| Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance JM Saunus, MCJ Quinn, AM Patch, JV Pearson, PJ Bailey, K Nones, ... The Journal of pathology 237 (3), 363-378, 2015 | 121 | 2015 |
| Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome PM Neilsen, JE Noll, RJ Suetani, RB Schulz, F Al-Ejeh, A Evdokiou, ... Oncotarget 2 (12), 1203, 2011 | 121 | 2011 |
| Tocotrienol as a potential anticancer agent MT Ling, SU Luk, F Al-Ejeh, KK Khanna Carcinogenesis 33 (2), 233-239, 2012 | 120 | 2012 |
| Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer F Al-Ejeh, PT Simpson, JM Sanus, K Klein, M Kalimutho, W Shi, ... Oncogenesis 3 (4), e100-e100, 2014 | 109 | 2014 |
| Rad51 supports triple negative breast cancer metastasis AP Wiegmans, F Al-Ejeh, N Chee, PY Yap, JJ Gorski, L Da Silva, ... Oncotarget 5 (10), 3261, 2014 | 105 | 2014 |
| Long noncoding RNAs CUPID1 and CUPID2 mediate breast cancer risk at 11q13 by modulating the response to DNA damage JA Betts, MM Marjaneh, F Al-Ejeh, YC Lim, W Shi, H Sivakumaran, ... The American Journal of Human Genetics 101 (2), 255-266, 2017 | 90 | 2017 |
| Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor F Al-Ejeh, W Shi, M Miranda, PT Simpson, AC Vargas, S Song, ... Journal of Nuclear Medicine 54 (6), 913-21, 2013 | 87 | 2013 |
| SCF-FBXO31 E3 ligase targets DNA replication factor Cdt1 for proteolysis in the G2 phase of cell cycle to prevent re-replication P Johansson, J Jeffery, F Al-Ejeh, RB Schulz, DF Callen, R Kumar, ... Journal of Biological Chemistry 289 (26), 18514-18525, 2014 | 83 | 2014 |
| Nutlin-3a is a potential therapeutic for ewing sarcoma KI Pishas, F Al-Ejeh, I Zinonos, R Kumar, A Evdokiou, MP Brown, ... Clinical Cancer Research, 2011 | 83 | 2011 |
| Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11 JE Noll, J Jeffery, F Al-Ejeh, R Kumar, KK Khanna, DF Callen, PM Neilsen Oncogene 31 (23), 2836-2848, 2012 | 78 | 2012 |
| Long-range regulators of the lncRNA HOTAIR enhance its prognostic potential in breast cancer MJG Milevskiy, F Al-Ejeh, JM Saunus, KS Northwood, PJ Bailey, JA Betts, ... Human molecular genetics 25 (15), 3269-3283, 2016 | 68 | 2016 |
| Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines F Al-Ejeh, D Croucher, M Ranson Experimental cell research 297 (1), 259-271, 2004 | 62 | 2004 |
| MITF and BRN2 contribute to metastatic growth after dissemination of melanoma JL Simmons, CJ Pierce, F Al-Ejeh, GM Boyle Scientific reports 7 (1), 10909, 2017 | 60 | 2017 |
